Pulmonary Hypertension | Treatment Algorithms: Claims Data Analysis | US | 2020
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. A wide array of drugs are available to treat PAH. Phosphodiesterase 5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs) are the most commonly prescribed first-line treatments; the more-efficacious prostacyclin therapies are used in later lines. Branded therapies dominate the PAH treatment algorithm, and combination therapy is common.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PAH patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PAH patients?
- How have Uptravi, Orenitram, Remodulin, and Adempas been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of PAH patients receive drug therapy within two years of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What percentage of PAH patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
KEY DRUGS COVERED
- Adcirca, Tracleer, Letairis, Opsumit, Tyvaso, Ventavis, Orenitram, Uptravi, Remodulin, Adempas, sildenafil, epoprostenol
Related Market Assessment Reports
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
